Company Monitoring Page for Clovis-Oncology

latest headlines for company on cafepharma

Clovis down after discontinuing rucaparib bladder cancer trial
BioCentury
Fri, 04/12/19 - 11:48 pm
Tags:
Clovis Oncology, Rubraca, bladder cancer
Early pancreatic cancer data give Clovis a new path in PARP market
Biopharma Dive
Tue, 04/2/19 - 04:22 pm
Tags:
pancreatic cancer, Clovis Oncology, AstraZeneca, PARP inhibitors, AACR, Rubraca, Lynparza
Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover
Yahoo/Zacks.com
Wed, 02/27/19 - 10:53 am
Tags:
Clovis Oncology, earnings
Want to buy Clovis? Step up. ‘Everybody knows where to find me,’ CEO says
Fierce Pharma
Fri, 01/11/19 - 08:12 pm
Tags:
M&A, Patrick Mahaffy, Pharma CEOs, Clovis Oncology, JPMHC 2019
JPM19: A biotech's M&A invitation, Editas' next CRISPR step and more from day 3
Biopharma Dive
Thu, 01/10/19 - 12:30 pm
Tags:
Editas, CRISPR, GSK, Tesaro, Clovis Oncology, M&A, AbbVie, JPMHC 2019
Clovis dips as Tesaro reveals more details of its acquisition
Biopharma Dive
Wed, 12/19/18 - 12:33 am
Tags:
Clovis Oncology, Tesaro, M&A
Could These Be the Next 2 Biotech Buyouts?
Motley Fool
Sun, 12/9/18 - 03:41 pm
Tags:
biotech, M&A, Agios Pharmaceuticals, Clovis Oncology
Clovis Oncology Prevails in European Patent Proceedings Related to Rubraca
CP Wire
Tue, 12/4/18 - 09:36 am
Tags:
Clovis Oncology, Europe, Rubraca
Tue, 12/4/18 - 09:13 am
Tags:
Clovis Oncology, Rubraca
7 drugs that raised eyebrows in Q3
Biopharma Dive
Thu, 11/15/18 - 11:50 pm
Tags:
Sanofi, Dupixent, Roche, Herceptin, AbbVie, Humira, Regeneron, Repatha, Clovis Oncology, Rubraca, GSK, Shingrix, Eli Lilly, Trulicity
PARP makers search for a way to break through
Biopharma Dive
Fri, 11/9/18 - 12:08 am
Tags:
AstraZeneca, Clovis Oncology, Tesaro, PARP inhibitors, ovarian cancer
Here's Why Clovis Oncology Stock Dropped a Whopping 60.4% in October
Motley Fool
Tue, 11/6/18 - 11:50 pm
Tags:
Clovis Oncology, Rubraca
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
Sat, 10/27/18 - 12:16 pm
Tags:
BrainStorm Cell Therapeutics, Allergan, Pfizer, Clovis Oncology, Acorda Therapeutics, Takeda, Agios Pharmaceuticals, Shire, Teva Pharmaceutical, AbbVie
PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
Fierce Pharma
Wed, 10/24/18 - 12:38 pm
Tags:
PARP inhibitors, physicians, Zejula, Rubraca, Lynparza, AstraZeneca, Merck, Tesaro, Clovis Oncology
Clovis' Rubraca leads to 44% ORR in Phase II for CRPC
BioCentury
Sat, 10/20/18 - 11:07 pm
Tags:
Clovis Oncology, Rubraca, rucaparib, metastatic castration-resistant prostate cancer
Clovis Oncology Receives Breakthrough Therapy Designation for Rubraca for Metastatic Castration Resistant Prostate Cancer
CP Wire
Tue, 10/2/18 - 09:55 am
Tags:
Clovis Oncology, Rubraca
Tue, 10/2/18 - 09:49 am
Tags:
Clovis Oncology, Rubraca
Clovis Oncology to Pay the SEC $20 Million for Misleading Investors
BioSpace
Wed, 09/19/18 - 11:29 am
Tags:
Clovis Oncology, SEC, investors, lung cancer, rociletinib
Clovis Starts Ph III Trial with Combination of Rubraca and Opdivo in Advanced Ovarian Cancer
CP Wire
Wed, 08/8/18 - 09:35 am
Tags:
Clovis Oncology, clinical trials, Bristol-Myers Squibb, Opdivo, ovarian cancer
Wed, 08/8/18 - 09:01 am
Tags:
Clovis Oncology, Rubraca, Opdivo, ovarian cancer

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.